FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc_20100128
Regeneron Pharmaceuticals Inc_20131212

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Regeneron Pharmaceuticals, Inc. patents


      
Recent patent applications related to Regeneron Pharmaceuticals, Inc.. Regeneron Pharmaceuticals, Inc. is listed as an Agent/Assignee. Note: Regeneron Pharmaceuticals, Inc. may have other listings under different names/spellings. We're not affiliated with Regeneron Pharmaceuticals, Inc., we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Regeneron Pharmaceuticals, Inc.-related inventors



Search recent Press Releases: Regeneron Pharmaceuticals, Inc.-related press releases
Count Application # Date Regeneron Pharmaceuticals, Inc. patents (updated weekly) - BOOKMARK this page
12014032221510/30/14 new patent  Methods of inhibiting tumor growth by antagonizing il-6 receptor
22014031524910/23/14Inducible eukaryotic expression system
32014028987609/25/14Mice that make heavy chain antibodies
42014027164209/18/14Il-33 antagonists and uses thereof
52014027165309/18/14Human antibodies to respiratory syncytial virus f protein and methods of use thereof
62014027165809/18/14Anti-il-33 antibodies and uses thereof
72014027168109/18/14High affinity human antibodies to human il-4 receptor
82014027309509/18/14Serum-free cell culture medium
92014027548909/18/14Apelin fusion proteins and uses thereof
102014028315809/18/14Rodents with conditional acvr1 mutant alleles
112014025539009/11/14Method of treating rheumatoid arthritis with an anti-il-6r antibody
122014025541909/11/14Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
132014025542909/11/14Methods of treating autoimmune diseases with dll4 antagonists
142014025599509/11/14High affinity antibodies to human il-6 receptor
152014024866409/04/14Readily isolated bispecific antibodies with native immunoglobulin format
162014024350408/28/14Antibodies comprising chimeric constant domains
172014024546608/28/14Humanized t cell co-receptor mice
182014024546708/28/14Genetically modified major histocompatibility complex mice
192014024546808/28/14Non-human animals with modified immunoglobulin heavy chain sequences
202014022002308/07/14Method of treating osteoarthritis with an antibody to ngf
212014021377307/31/14Adam6 mice
222014019655007/17/14Systems and devices for sample handling
232014019976107/17/14Promoter-regulated differentiation-dependent self-deleting cassette
242014019340207/10/14Anti-pdgfr-beta antibodies and uses thereof
252014019459707/10/14Modified chimeric polypeptides with improved pharmacokinetic properties
262014018990007/03/14Mirna-regulated differentiation-dependent self-deleting cassette
272014017887906/26/14Compositions and methods for modifying cells
282014017990306/26/14High affinity human antibodies to human protease-activated receptor 2
292014015470106/05/14Humanized fc gamma r mice
302014015568906/05/14Methods of modifying genes in eukaryotic cells
312014015744506/05/14Low affinity fcgr deficient mice
322014013797805/22/14System and methods for use in dispensing biopharmaceutical materials
332014013797805/22/14System and methods for use in dispensing biopharmaceutical materials
342014013416905/15/14Methods of treating ovarian cancer with dll4 antagonists
352014013418905/15/14Anti-prokineticin receptor (prokr) antibodies and uses thereof
362014013471905/15/14Recombinant cell surface capture proteins
372014013727505/15/14Hybrid light chain mice
382014013416905/15/14Methods of treating ovarian cancer with dll4 antagonists
392014013418905/15/14Anti-prokineticin receptor (prokr) antibodies and uses thereof
402014013471905/15/14Recombinant cell surface capture proteins
412014013727505/15/14Hybrid light chain mice
422014013019305/08/14Mice that make vl binding proteins
432014013019405/08/14Mice that make vl binding proteins
442014013019305/08/14Mice that make vl binding proteins
452014013019405/08/14Mice that make vl binding proteins
462014012010905/01/14Human antibodies to human tnf-like ligand 1a (tl1a)
472014012010905/01/14Human antibodies to human tnf-like ligand 1a (tl1a)
482014011293004/24/14Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
492014011293004/24/14Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
502014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
512014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
522014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
532014008829503/27/14Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
542014008829503/27/14Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
552014008276003/20/14Non-human animals expressing ph-sensitive immunoglobulin sequences
562014008276003/20/14Non-human animals expressing ph-sensitive immunoglobulin sequences
572014007256303/13/14Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
582014007258303/13/14Methods for treating atopic dermatitis by administering an il-4r antagonist
592014007297903/13/14Isolating cells expressing secreted proteins
602014007298003/13/14Isolating cells expressing secreted proteins
612014007301003/13/14Methods of modifying eukaryotic cells
622014007558603/13/14Parental cell lines for making cassette-free f1 progeny
632014007256303/13/14Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
642014007258303/13/14Methods for treating atopic dermatitis by administering an il-4r antagonist
652014007297903/13/14Isolating cells expressing secreted proteins
662014007298003/13/14Isolating cells expressing secreted proteins
672014007301003/13/14Methods of modifying eukaryotic cells
682014007558603/13/14Parental cell lines for making cassette-free f1 progeny
692014005690302/27/14Human antibodies to gfr alpha 3 and methods of use thereof
702014005690702/27/14Anti-asic1 antibodies and uses thereof
712014004473002/13/14Anti-pcsk9 antibodies with ph-dependent binding characteristics
722014004106802/06/14Methods of modifying eukaryotic cells
732014003333601/30/14Methods of modifying eukaryotic cells
742014003333701/30/14Methods of modifying eukaryotic cells
752014002363701/23/14Methods of modifying eukaryotic cells
762014001722801/16/14Humanized light chain mice
772014001722901/16/14Methods of modifying eukaryotic cells
782014001723801/16/14Methods of modifying eukaryotic cells
792014001769501/16/14Isolating cells expressing secreted proteins
802014001778101/16/14Methods of modifying eukaryotic cells
812014001778201/16/14Methods for modifying eukaryotic cells
822014001852201/16/14Methods of modifying eukaryotic cells
832014002012401/16/14Methods of modifying eukaryotic cells
842014002012501/16/14Methods of modifying eukaryotic cells
852014001345601/09/14Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
862014001345701/09/14Methods of modifying eukaryotic cells
872013034453812/26/13Human antibodies to the glucagon receptor
882013034010412/19/13Humanized il-7 rodents
892013033305712/12/13Humanized non-human animals with restricted immunoglobulin heavy chain loci
902013033305712/12/13Humanized non-human animals with restricted immunoglobulin heavy chain loci
912013032326012/05/13Stabilized formulations containing anti-dll4 antibodies
922013032326112/05/13Purified antibody composition
932013032378812/05/13Production cell line enhancers
942013032379012/05/13Human lambda light chain mice
952013032379112/05/13Restricted immunoglobulin heavy chain mice
962013032664712/05/13Human lambda light chain mice
972013030967011/21/13Nuclease-mediated targeting with large targeting vectors
982013031212811/21/13Promoter-regulated differentiation-dependent self-deleting cassette
992013031212911/21/13Promoter-regulated differentiation-dependent self-deleting cassette
1002013029509711/07/13Human antibodies to fel d1 and methods of use thereof
1012013028075810/24/13Fusion polypeptides capable of activating receptors
1022013027307010/17/13Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
1032013026657410/10/13Human antibodies to human angiopoietin-like protein 4
1042013025987610/03/13Anti-hla-b*27 antibodies and uses thereof
1052013025988110/03/13Fusion polypeptides capable of activating receptors
1062013026105610/03/13Vegf antagonist formulations
1072013025172809/26/13Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
1082013025491109/26/13Adam6 mice
1092013024377509/19/13Multispecific antigen-binding molecules and uses thereof
1102013024378409/19/13Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
1112013024723409/19/13Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
1122013024723509/19/13Mice that produce antigen-binding proteins with ph-dependent binding characteristics
1132013024723609/19/13Non-human animals expressing ph-sensitive immunoglobulin sequences
1142013023053109/05/13Human antibodies to clostridium difficile toxins
1152013023053309/05/13Methods of treating systemic lupus erythematosus (sle) using anti-cd48 antibodies
1162013021654708/22/13Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
1172013021654708/22/13Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
1182013020949208/15/13Anti-tie2 antibodies and uses thereof
1192013021013708/15/13Methods of modifying eukaryotic cells
1202013021271908/15/13Humanized rodents that express heavy chain containing vl domains
1212013020949208/15/13Anti-tie2 antibodies and uses thereof
1222013021013708/15/13Methods of modifying eukaryotic cells
1232013021271908/15/13Humanized rodents that express heavy chain containing vl domains
1242013019587808/01/13Anti-asic1 antibodies and uses thereof
1252013019887908/01/13Humanized universal light chain mice
1262013019888008/01/13Mice expressing a limited immunoglobulin light chain repertoire
1272013019587808/01/13Anti-asic1 antibodies and uses thereof
1282013019887908/01/13Humanized universal light chain mice
1292013019888008/01/13Mice expressing a limited immunoglobulin light chain repertoire
1302013018679707/25/13Stabilized formulations containing anti-ang2 antibodies
1312013018927707/25/13Stabilized formulations containing anti-pcsk9 antibodies
1322013018679707/25/13Stabilized formulations containing anti-ang2 antibodies
1332013018927707/25/13Stabilized formulations containing anti-pcsk9 antibodies
1342013018420507/18/13Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
1352013018581907/18/13Genetically modified major histocompatibility complex animals
1362013018582007/18/13Genetically modified major histocompatibility complex animals
1372013018582107/18/13Common light chain mouse
1382013018420507/18/13Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
1392013018581907/18/13Genetically modified major histocompatibility complex animals
1402013018582007/18/13Genetically modified major histocompatibility complex animals
1412013018582107/18/13Common light chain mouse
1422013017114907/04/13Anti-angptl3 antibodies and uses thereof
1432013017114907/04/13Anti-angptl3 antibodies and uses thereof
1442013016478606/27/13Fucosylation-deficient cells
1452013016478606/27/13Fucosylation-deficient cells
1462013015731306/20/13High affinity antibodies to human il-6 receptor
1472013016015306/20/13Humanized light chain mice
1482013015731306/20/13High affinity antibodies to human il-6 receptor
1492013016015306/20/13Humanized light chain mice
1502013014974406/13/13Methods for producing a fusion protein capable of binding vegf
1512013014974406/13/13Methods for producing a fusion protein capable of binding vegf
1522013013710105/30/13Methods of modifying eukaryotic cells
1532013013710105/30/13Methods of modifying eukaryotic cells
1542013012972205/23/13Methods for treating cancer by administering an anti-ang-2 antibody
1552013012983005/23/13Polymer protein microparticles
1562013013037205/23/13Enhanced expression and stability regions
1572013013038805/23/13Methods of modifying eurakyotic cells
1582013012972205/23/13Methods for treating cancer by administering an anti-ang-2 antibody
1592013012983005/23/13Polymer protein microparticles
1602013013037205/23/13Enhanced expression and stability regions
1612013013038805/23/13Methods of modifying eurakyotic cells
1622013012200305/16/13Methods of inhibiting tumor growth by antagonizing il-6 receptor
1632013012200705/16/13Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1642013012200305/16/13Methods of inhibiting tumor growth by antagonizing il-6 receptor
1652013012200705/16/13Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1662013011787305/09/13Humanized il-6 and il-6 receptor
1672013011787305/09/13Humanized il-6 and il-6 receptor
1682013010905305/02/13Genetically modified t cell receptor mice
1692013011161605/02/13Genetically modified major histocompatibility complex mice
1702013011161705/02/13Genetically modified major histocompatibility complex mice
1712013009556504/18/13Mirna-regulated differentiation-dependent self-deleting cassette
1722013009628704/18/13Restricted immunoglobulin heavy chain mice
1732013008429704/04/13Anti-erbb3 antibodies and uses thereof
1742013008463504/04/13Cell culture compositions capable of producing a vegf-binding fusion polypeptide
1752013008526604/04/13Anti-pcsk9 antibodies with ph-dependent binding characteristics
1762013007867503/28/13High affinity human antibodies to human il-4 receptor
1772013006483403/14/13Methods for treating hypercholesterolemia using antibodies to pcsk9
1782013004549202/21/13Methods for making fully human bispecific antibodies using a common light chain
1792013003490202/07/13Fusion polypeptides capable of activating receptors
1802013002889201/31/13Method of treating osteoarthritis with an antibody to ngf
1812012032210812/20/12Adam6 mice
1822012032349712/20/12Non-hypergeometric overlap probability
1832012025809810/11/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
1842012026035710/11/12Low affinity fcgr deficient mice
1852012019589608/02/12Igf-1 fusion polypeptides and therapeutic uses thereof
1862012018963507/26/12Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
1872012019230007/26/12Common light chain mouse
1882012017868307/12/12Vegf antagonist formulations
1892012016468806/28/12High affinity human antibodies to human nerve growth factor
1902012013501005/31/12High affinity human antibodies to human il-4 receptor
1912012012867905/24/12Human antibodies to the glucagon receptor
1922012011464505/10/12Use of il-1 antagonists to treat pseudogout
1932012011465405/10/12Human antibodies to human tnf-like ligand 1a (tl1a)
1942012011466505/10/12Human antibodies to human rankl
1952012009756504/26/12Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
1962012010014504/26/12Methods for treating b-cell lymphoma by administering an anti-cd20 antibody
1972012010103504/26/12Vegf antagonist formulations
1982012009382404/19/12Methods for treating pruritus by administering an antibody that specifically binds human par2
1992012009657204/19/12Mice that make vl binding proteins
2002012008792904/12/12Vegf antagonist formulations for intravitreal administration
2012012008300004/05/12Neuropeptide release assay for sodium channels
2022012007679003/29/12Anti-cd48 antibodies and uses thereof
2032012007086103/22/12Human lambda light chain mice
2042012007300403/22/12Hybrid light chain mice
2052012006462103/15/12Cell culture compositions capable of producing a vegf-binding fusion polypeptide
2062012005207203/01/12High affinity human antibodies to human il-4 receptor
2072012004544002/23/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
2082012002140901/26/12Common light chain mouse
2092012001496801/19/12Stabilized formulations containing anti-ngf antibodies
2102012000369701/05/12High affinity antibodies to human il-6 receptor
2112011031834212/29/11Methods of using il-1 antagonists to treat autoinflammatory disease
2122011031153712/22/11Methods of using il-1 antagonists to treat familial mediterranean fever (fmf)
2132011030796612/15/11Mice expressing human voltage-gated sodium channels
2142011030796812/15/11Production of fertile xy animals from xy es cells
2152011029363012/01/11Antibodies to human gdf8
2162011028337611/17/11Methods of modifying eukaryotic cells
2172011026918711/03/11High affinity human antibodies to human il-18 receptor
2182011025614810/20/11Methods for treating hypercholesterolemia using antibodies to pcsk9
2192011025655610/20/11Humanized fcgr mice
2202011025658710/20/11High affinity human antibodies to human nerve growth factor
2212011025760110/20/11Vegf antagonist formulations for intravitreal administration
2222011025871010/20/11Methods of modifying eukaryotic cells
2232011019545408/11/11Common light chain mouse
2242011018917608/04/11Methods of treating diseases with dll4 antagonists
2252011018920008/04/11Methods of treating autoimmune diseases with dll4 antagonists
2262011017124107/14/11Stabilized formulations containing anti-interleukin-6 (il-6) antibodies
2272011016565007/07/11Fusion polypeptides capable of activating receptors
2282011015901506/30/11Human antibodies to human angiopoietin-like protein 4
2292011015090506/23/11Human antibodies to human delta like ligand 4
2302011015451206/23/11Humanized fc gamma r mice
2312011014593706/16/11Mice that make heavy chain antibodies
2322011010479905/05/11Multifunctional alleles
2332011008168104/07/11Human antibodies to human cd20 and method of using thereof
2342011006590203/17/11High affinity human antibodies to pcsk9
2352011005909503/10/11High affinity human antibodies to human protease-activated receptor-2
2362011004119602/17/11Mirna-regulated differentiation-dependent self-deleting cassette
2372011004119702/17/11Promoter-regulated differentiation-dependent self-deleting cassette
2382011002728602/03/11High affinity human antibodies to human angiopoietin-2
2392011002034201/27/11Igf-1 fusion polypeptides and therapeutic uses thereof
2402011001420801/20/11Method of treating osteoarthritis with an antibody to ngf
2412011000837401/13/11Use of il-1 antagonists to treat gout
2422010033010612/30/10Method of treating cancer with dll4 antagonist and chemotherapeutic agent
2432010033152712/30/10Readily isolated bispecific antibodies with native immunoglobulin format
2442010031662712/16/10Human antibodies to human il-6 receptor
2452010031663612/16/10Method of treating rheumatoid arthritis with an il-6r antibody
2462010030443612/02/10Fucosylation-deficient cells
2472010029110711/18/10High affinity human antibodies to human il-4 receptor
2482010029162611/18/10Enhanced expression and stability regions
2492010027993311/04/10Vegf antagonist formulations


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Regeneron Pharmaceuticals, Inc. in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Regeneron Pharmaceuticals, Inc. with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         


FreshNews promo